The civic-run King Edward Memorial Hospital in Mumbai on Wednesday began phase II and III trials of the Oxford Covishield vaccine for COVID-19, an official said. The hospital, located in Parel......
United Kingdom-headquartered pharmaceutical giant AstraZeneca (AZ) has admitted that in 'very rare cases' its Covid vaccine can cause a blood clot related side effect but the causal link is......
The government has committed to buy from the Serum Institute further 4.5 crore doses of Oxford COVID-19 vaccine, Covishield, at a price of Rs 200 per shot plus applicable taxes by April, in......
In the wake of pharmaceutical giant AstraZeneca admitting in a UK court that its COVID vaccine can cause blood clots in rare cases, a group of doctors on Thursday expressed deep concern over the......
The government on Monday placed a purchase order with Serum Institute of India for 1.1 crore doses of Oxford COVID-19 vaccine, Covishield, each costing Rs 210, including the GST, and committed to......
The institute expects to complete both, phase-2 and 3 trials in India by the end of this year. Pune's Serum Institute of India (SII) is all set to start phase-2 clinical trials of the Oxford......
Stocks of Oxford COVID-19 vaccine, Covishield, are likely to start moving out of Serum Institute of India's facility here on early Tuesday morning, days ahead of the nationwide inoculation drive,......
There was speculation that a one-time special Covid-19 cess would be imposed and that it would raise an estimated Rs 18,000 crore. Currently three vaccines - Bharat Biotech’s Covaxin,......
'Once the trials are successful in India and the UK, we are certain that COVISHIELD will be one of the first vaccines to be introduced.' IMAGE: The Reference Center for Special Immunobiologicals......